American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Humacyte stock may fail to sustain today’s gains: find out more

by admin December 21, 2024
December 21, 2024
Humacyte stock may fail to sustain today’s gains: find out more

Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product from the US Food and Drug Administration (FDA).

Regulatory approval for the company’s bioengineered human tissue marks a major step forward in regenerative medicine and trauma care.

Humacyte stock sure has made its investors a happy lot today – but a more important question is: would it be able to sustain its recent gains heading into the next year?

Unfortunately, there’s reason to believe it may not.  

Insiders have been unloading Humacyte stock

Recent insider moves have not been particularly encouraging in Humacyte.

Brady W. Dougan – its board member who’s married to chief executive Laura Niklason sold a total of 1.5 million shares of Humacyte via his LLC called Ayabudge for $6.6 million in November.   

Insider selling is often considered negative because it signals a lack of confidence in the company’s future prospect.

That’s because executives and board members usually have more information than an average investor.

So, when they trim or sell their stake entirely, it typically suggests they see the stock as overvalued or expect the company to face challenges ahead.

If any of those assumptions prove true, Humacyte stock may end up losing today’s gain over the next few weeks.

HUMA is yet to turn a quarterly revenue

FDA’s approval for Humacyte’s SYMVESS sure is a big news for regenerative medicine.

But one must not forget that it continues to be a pre-revenue company for now. Humacyte lost $39.2 million in its third financial quarter – a significant increase from $26 million a year ago.

The Nasdaq listed firm ended its Q3 with $71 million in cash, cash equivalents, and restricted cash, which suggests it may have to dilute its shareholders to fund operations moving forward.  

What’s also worth mentioning is that Humacyte stock was worth about $3.0 before today’s gain.

So, there’s possibility that investors are manipulating its modest price tag to pump it up before unloading all of it to lock in sizeable profits.

Humacyte faces litigation for misleading investors

Finally, Humacyte is currently grappling with a class-action lawsuit over allegedly misleading investors about the regulatory compliance of its production facilities.

The biotech firm has failed to share critical information with its investors about its business and operations.

If such allegations prove to be true, “the company’s conduct constitutes a serious violation of securities laws,” as per Reed Kathrein of Hagens Berman – a law firm investigating the matter.

And it’s not like Humacyte stock pays a dividend to reward its shareholders for their patience through the turbulence.

Nonetheless, Wall Street has a consensus “buy” rating on Humacyte shares with price targets going as high as $25 at writing.

The post Humacyte stock may fail to sustain today’s gains: find out more appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Why Nike’s CEO believes turnaround efforts could hurt in the short term
next post
Novo Nordisk stock just tanked 25%: here’s what happened

Related Posts

Asian shares display mixed performance amidst trade tensions...

February 12, 2025

Why is Trump calling for a repeal of...

March 5, 2025

Very bad news for the popular SCHD ETF

November 21, 2024

AMC stock price forecast: will it short squeeze...

February 24, 2025

Asia markets mixed as Albanese wins second term;...

May 5, 2025

Tata Motors stock enters a correction after a...

September 11, 2024

Stephanie Link reveals her favourite retail stocks after...

May 18, 2025

Firefly Aerospace surges over 50% in Nasdaq debut,...

August 8, 2025

US stocks rebound as White House signals trade...

April 12, 2025

Groupon stock price has become overbought: is it...

June 15, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • FBI raid on John Bolton’s home in Washington linked to classified documents

      August 25, 2025
    • Argentine senate deals blow to Milei’s austerity agenda with university budget boost

      August 25, 2025
    • Jackson Hole Symposium: what Powell said about economic effects of Trump’s tariffs

      August 25, 2025
    • At Jackson Hole, Fed Chair Powell signals possible cuts while warning of uncertainty

      August 25, 2025
    • Trump threatens to fire Fed Governor Lisa Cook amid mortgage fraud allegations

      August 25, 2025

    Categories

    • Business (3,763)
    • Investing (2,783)
    • Latest News (2,048)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved